NCT07290595 Comparative Analysis Of Dexmedetomidine And Dexamethasone As An Adjuvant To 0.5%Ropivacaine On Onset Of Ultrasound Guided Supraclavicular Brachial Plexus Block In Patients Undergoing Upper Limb Surgeries
| NCT ID | NCT07290595 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Sahiwal medical college sahiwal |
| Condition | Post Operative Analgesia |
| Study Type | INTERVENTIONAL |
| Enrollment | 66 participants |
| Start Date | 2025-01-13 |
| Primary Completion | 2026-02-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 66 participants in total. It began in 2025-01-13 with a primary completion date of 2026-02-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To compare the efficacy of dexmedetomidine and dexamethasone as an adjuvant to 0.5%ropivacaine on onset of ultrasound guided supraclavicular brachial plexus block in patients undergoing upper limb surgeries. Ropivacaine hydrochloride, a long acting local anesthetic, is commonly used for supraclavicular block owing to its favorable safety profile especially in terms of minimal cardiotoxicity and less motor block. Dexmedetomidine, a highly selective alpha-2 adrenergic agonist, enhances the quality of supraclavicular block by providing sedation and analgesia while potentially prolonging the duration of block through hyperpolarization of nerve fibers. While, Dexamethasone, a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties, prolongs duration of analgesia by reducing perineural inflammation and inhibiting nociceptive signal transmission. Supraclavicular brachial plexus block offers dense anesthesia for surgical procedures at or distal to the elbow with relatively high success rate, once described as "spinal of the arm". Moreover, supraclavicular brachial plexus block is an excellent alternative to general anesthesia in upper limb surgeries.
Eligibility Criteria
Inclusion Criteria * Patients scheduled for upper limb surgery below mid-humerus level * Patients aged 18 to 70 years * Patients with ASA class I, II and III * Male and non-pregnant females Exclusion Criteria * Patients refusal * Patients with pre-existing peripheral neuropathy of the upper limb * Patients with the Infection at block site * Patients with history of ischemic heart disease * Patients with bleeding disorder or deranged coagulation profile * Patients with known history of allergy to local anaesthetic or any other drugs used
Contact & Investigator
Adeel Riaz, MD
STUDY DIRECTOR
Sahiwal medical college sahiwal
Frequently Asked Questions
Who can join the NCT07290595 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Post Operative Analgesia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07290595 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07290595 currently recruiting?
Yes, NCT07290595 is actively recruiting participants. Contact the research team at maryammaqsood448@gmail.com for enrollment information.
Where is the NCT07290595 trial being conducted?
This trial is being conducted at Sāhīwāl, Pakistan.
Who is sponsoring the NCT07290595 clinical trial?
NCT07290595 is sponsored by Sahiwal medical college sahiwal. The principal investigator is Adeel Riaz, MD at Sahiwal medical college sahiwal. The trial plans to enroll 66 participants.